Insider Selling: James Oliviero III Sells 1,475 Shares of Keryx Biopharmaceuticals Stock (KERX)
Keryx Biopharmaceuticals (NASDAQ:KERX) CFO James Oliviero III sold 1,475 shares of the company’s stock in a transaction that occurred on Thursday, October 3rd. The shares were sold at an average price of $10.25, for a total transaction of $15,118.75. Following the completion of the transaction, the chief financial officer now directly owns 555,929 shares in the company, valued at approximately $5,698,272. The sale was disclosed in a filing with the SEC, which can be accessed through this link.
Separately, analysts at Maxim Group raised their price target on shares of Keryx Biopharmaceuticals from $9.00 to $12.00 in a research note to investors on Thursday, August 1st. They now have a “buy” rating on the stock. Ten equities research analysts have rated the stock with a buy rating, Keryx Biopharmaceuticals presently has a consensus rating of “Buy” and a consensus target price of $12.00.
Shares of Keryx Biopharmaceuticals (NASDAQ:KERX) traded down 2.90% on Monday, hitting $10.04. The stock had a trading volume of 1,181,488 shares. Keryx Biopharmaceuticals has a 52 week low of $2.23 and a 52 week high of $10.92. The stock’s 50-day moving average is $9.34 and its 200-day moving average is $8.33. The company’s market cap is $821.4 million.
Keryx Biopharmaceuticals (NASDAQ:KERX) last announced its earnings results on Thursday, August 1st. The company reported ($0.14) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.10) by $0.04. During the same quarter in the previous year, the company posted ($0.02) earnings per share.
Keryx Biopharmaceuticals, Inc (NASDAQ:KERX) is a biopharmaceutical company focused on the acquisition, development and commercialization of pharmaceutical products for the treatment of cancer and renal disease.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.